Group 1 - Sampo Group has received approval from the Swedish FSA to include its Danish operations under Topdanmark in the Group's Partial Internal Model (PIM) [1] - The extended model is expected to reduce the group-level solvency capital requirement by approximately EUR 90 million as of 31 December 2025 [2] - The implementation of the extended PIM will commence in the first quarter of 2026 [2]

Core Insights - ONWARD Medical N.V. is set to report its Full-Year 2025 Financial Results and provide a business update on March 31, 2026 [1][2] Company Overview - ONWARD Medical is a leading neurotechnology company focused on therapies to restore movement, function, and independence for individuals with spinal cord injuries and other movement disabilities [3] - The company has developed proprietary ARC Therapy, which has received 10 Breakthrough Device Designations from the FDA [3] - The ARC-EX System is commercially available in the US and Europe, while the investigational ARC-IM system is being developed to address unmet needs such as blood pressure instability after spinal cord injury [3] - The company is headquartered in the Netherlands, with additional facilities in Switzerland and the US [4] Future Developments - The ARC-IM system is designed to be paired with brain-computer interfaces (BCI) and artificial intelligence (AI) to facilitate thought-driven movement [3]

Core Viewpoint - Questerre Energy Corporation emphasizes the importance of local natural gas development in Quebec for enhancing energy security amid evolving geopolitical and economic conditions [2]. Group 1: Company Developments - Questerre has completed a corporate reorganization, with economic rights to Quebec assets now held by Series 2 Preferred shareholders [1]. - The company is committed to developing its natural gas discovery in the Québec Utica, recognized as a significant undeveloped resource in Eastern Canada [3][4]. - Questerre is working cooperatively with the Government of Quebec to meet obligations under Bill 21, including demonstrating $11 million in liquidity for future well abandonments [2]. Group 2: Environmental Considerations - A peer-reviewed environmental study by CIRAIG highlights the significant environmental benefits of local gas development [2]. - The Government of Quebec's Strategic Environmental Assessment indicates that net environmental impacts from local gas development are manageable [2]. Group 3: Strategic Goals - The company aims to balance economic, environmental, and societal factors in the energy industry, advocating for public involvement in energy decisions [5]. - Questerre believes that the future of the energy industry relies on clean technologies and innovation to responsibly produce and utilize energy [4].

Core Insights - Basilea Pharmaceutica Ltd has initiated the first-in-human phase 1 study of BAL2420, a novel LptA inhibitor targeting severe bacterial infections [1][3] Company Overview - Basilea is a commercial-stage biopharmaceutical company founded in 2000, headquartered in Switzerland, focused on developing innovative drugs for severe bacterial and fungal infections [5] - The company has successfully launched two hospital brands: Cresemba for invasive fungal infections and Zevtera for bacterial infections [5] Product Development - BAL2420 is a novel antibiotic targeting LptA, crucial for Gram-negative bacteria, showing potent bactericidal activity against resistant strains like E. coli and K. pneumoniae [2] - The phase 1 study is a single-center, randomized, dose-escalation, double-blind, and placebo-controlled trial assessing intravenous administration of BAL2420 [3] - The study aims to evaluate the safety, tolerability, and pharmacokinetics of BAL2420, with data expected to support further clinical development [3] Industry Context - The CDC and WHO have identified Enterobacteriaceae, including carbapenem-resistant strains, as high-priority pathogens, highlighting the urgent need for new antibiotic treatments [2] - The development of BAL2420 has been supported by CARB-X since 2020, advancing from the Hit-to-Lead stage to the first-in-human study [4]

Core Insights - Novartis will present over 20 abstracts from its immunology portfolio at the American Academy of Dermatology (AAD) Annual Meeting, showcasing advancements in treatments for chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) [1][2][3] Immunology Portfolio Highlights - New data on Rhapsido (remibrutinib) will be presented, focusing on early symptom improvement in CSU patients, with significant changes in daily itch and hives severity scores observed as early as week 1 [2][4] - Long-term efficacy data for Cosentyx (secukinumab) will be shared, reinforcing its continuous use in HS and psoriasis, including a matched adjusted indirect comparison of its safety and flare prevention against bimekizumab [4][5] Key Abstracts - Notable abstracts include: - "Early symptom improvement with remibrutinib in chronic spontaneous urticaria" (Abstract 71668) [3] - "Flare prevention and safety of secukinumab vs bimekizumab in hidradenitis suppurativa" (Abstract 76852) [5] - "Effectiveness of Secukinumab in Preventing Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis" (Abstract 73859) [5] Commitment to Innovation - Novartis emphasizes its dedication to advancing science in immunology, aiming to provide relief for patients with autoimmune diseases through a robust pipeline and innovative treatments [6]

Core Viewpoint - OVH Groupe has announced a share buyback program authorized by the General Shareholders' Meeting on February 12, 2026, aimed at enhancing shareholder value and supporting market liquidity [1][4]. Group 1: Share Buyback Program Details - The share buyback program will involve purchasing shares of OVH Groupe listed on Euronext Paris under ISIN code FR0014005HJ9 (Ticker: OVH) [2][8]. - The program allows for the acquisition of up to 10% of the company's share capital, with the total number of shares repurchased not exceeding this limit at any time [7]. - The maximum purchase price for shares under this program is set at 200% of the offer price at the time of the company's admission to trading, with a total budget not exceeding €50,000,000 [9][14]. Group 2: Objectives and Uses of Shares - The shares repurchased may be used for various purposes, including stock option plans, employee share allocations, and ensuring market liquidity through a liquidity contract [4][6]. - The company has previously entered into a liquidity contract with Rothschild Martin Maurel, allocating €5,000,000 for this purpose [5]. Group 3: Duration and Implementation - The duration of the share buyback program is set for 18 months, starting from the authorization date, concluding on August 12, 2027 [11]. - The acquisition of shares can occur at any time within legal limits, excluding public offer periods, and can be executed through various means including regulated markets and over-the-counter transactions [10]. Group 4: Company Overview - OVHcloud is a leading European cloud provider, operating over 500,000 servers across 46 data centers globally, serving 1.6 million customers in over 140 countries [12]. - The company focuses on providing a sustainable cloud solution with a strong emphasis on performance, predictable pricing, and data sovereignty [12].

Core Insights - STMicroelectronics has commenced volume production of STM32 microcontrollers manufactured in China, marking a significant advancement in its global supply chain strategy [1][8] - The collaboration with Huahong enables STMicroelectronics to establish a dual supply chain for 40nm MCU products, ensuring compatibility with global quality standards [3][4] Group 1: Manufacturing and Supply Chain - The first batch of STM32 wafers produced in China is being delivered to local customers, with plans for additional STM32 families to enter local production in 2026 [1][8] - STMicroelectronics has developed a fully localized STM32 supply chain, covering all stages from wafer manufacturing to chip packaging and testing [3] - The partnership with Huahong leverages identical technology and quality control standards as ST's global fabs, ensuring seamless product compatibility [4] Group 2: Product Offerings - The initial product from the China supply chain is the STM32H7 series, aimed at high-performance applications such as industrial systems and smart home devices, with mass production already underway [6][8] - Future products include the STM32H5 series, which focuses on performance and security for various consumer and industrial applications, with mass production planned by the end of 2026 [6][8] - The entry-level STM32C5 series is also set to target applications in industrial automation and consumer electronics, with mass production expected by the end of 2026 [9] Group 3: Strategic Commitment - STMicroelectronics emphasizes its commitment to Chinese customers by providing a reliable local microcontroller supply chain, enhancing responsiveness to market needs [2][5] - The dual-supply model offers customers the choice between locally manufactured MCUs and those produced outside China, while maintaining consistent global quality [5]

Core Insights - Willis has partnered with Circle Asia to launch a new art insurance facility tailored for individual collectors and art galleries in Asia, marking the first of its kind in the region [1][5] Group 1: Insurance Facility Features - The new facility offers a significantly lower entry premium, making comprehensive coverage more accessible for collectors and galleries [2][8] - It provides a single, streamlined solution that covers fine art, jewellery, and specie collections, addressing the evolving needs of Asia's growing art market [2][8] - The facility supports one-off exhibition and transit coverage with comprehensive insurance terms and expedited turnaround [2] Group 2: Market Context and Demand - Asia's fine arts market is rapidly growing, driven by the increasing participation of young and affluent collectors, highlighting a demand for efficient insurance solutions [3][6] - Clients now expect fast turnaround and efficient service for their coverage and claims handling, indicating a shift in market expectations [3] Group 3: Partnership Benefits - The collaboration combines Willis' specialist arts insurance expertise with Circle Asia's digital platform, enhancing efficiency, underwriting access, and processing speed [4][5] - This partnership aims to simplify complex policy structures while delivering a high-quality, digitally enabled fine arts solution [4][5] - The joint effort reflects a commitment to developing innovative, client-centric insurance solutions and expanding specialty capabilities in Hong Kong [5][6] Group 4: Operational Enhancements - The facility features end-to-end management by Willis' Fine Art team via Circle's digital platform, improving communication, accountability, and turnaround time compared to conventional processes [8] - Tailored terms and premiums are structured to support the facility's objectives, catering to the unique needs of individual arts collectors [8]

Core Viewpoint - HUTCHMED has initiated a registrational Phase III clinical trial for HMPL-760 in combination with R-GemOx for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in China, with the first patient dosed on March 20, 2026 [1]. Group 1: Clinical Trial Details - The Phase III trial is randomized, double-blind, and positive controlled, evaluating the efficacy, safety, and pharmacokinetics of HMPL-760 combined with R-GemOx versus placebo with R-GemOx in DLBCL patients who are relapsed or refractory after prior treatments [3]. - The trial aims to enroll approximately 240 patients and is led by Professor Weili Zhao from Ruijin Hospital, Shanghai [4]. Group 2: Background on DLBCL and HMPL-760 - DLBCL is the most common form of aggressive non-Hodgkin lymphoma, accounting for about 40% of all NHL cases in China, with an estimated 81,000 new cases diagnosed in 2022 [2]. - HMPL-760 is a third-generation, non-covalent BTK inhibitor that has shown promising results in a Phase II study, demonstrating improvements in overall response rate, complete response rate, progression-free survival, and overall survival compared to R-GemOx alone [5]. Group 3: Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [7]. - The company retains all rights to HMPL-760 worldwide, indicating its commitment to advancing this investigational therapy [6].

Core Insights - Nissay Asset Management has selected Triton from Virtu Financial to enhance its trading operations across global markets [1][4] Company Overview - Virtu Financial, Inc. is a leading provider of global, multi-asset financial services, delivering liquidity and innovative products throughout the investment cycle [1][7] - Nissay Asset Management, established in 1995, is a 100% subsidiary focused on asset management, catering to pension funds and individual investors for long-term asset building [2] Product and Technology - Triton is a multi-asset execution management system (EMS) that facilitates trading across various asset classes, including equities, ETFs, futures, options, FX, and fixed income, connecting over 700 brokers and venues [3] - The system is designed for active traders, providing technology that supports traders throughout the lifecycle of a trade [3] Implementation and Benefits - Nissay Asset Management chose Triton for its seamless integration of Algo Wheel and Analytics capabilities, which are tailored to meet specific internal requirements [4] - The implementation has centralized key functions such as automated execution and RFQs into a single interface, significantly enhancing operational efficiency [5] - Nissay AM anticipates that leveraging Transaction Cost Analysis (TCA) will further optimize execution performance [5] Client Relationship and Industry Recognition - Nissay AM highlighted Virtu's strong client satisfaction and industry recognition among Japanese institutional peers as key factors in their selection [6] - The long-standing partnership and previous adoption of Virtu's TCA demonstrate Virtu's commitment to supporting institutional clients with evolving technology solutions [6] Strategic Validation - The selection of Triton validates Virtu's strategy of providing integrated, best-in-class technology solutions that adapt to unique client workflows [7]